Total neoadjuvant therapy for rectal cancer
- PMID: 29807808
- DOI: 10.1016/j.canrad.2018.01.004
Total neoadjuvant therapy for rectal cancer
Abstract
While outcomes for patients with locally advanced disease have improved considerably with combined modality therapy, there is now an emphasis on developing risk-adapted treatment strategies. Moreover, the primary cause of death from locally advanced rectal cancer is related to distant progression, which now exceeds the rate of local failure. Thus, the necessity to optimally address micrometastatic disease has led to increasing interest in delivering chemotherapy in the neoadjuvant setting rather than in the postoperative setting. This review critically appraises the emerging literature on the options for sequencing of therapy, focusing on the total neoadjuvant therapy paradigm as well as emerging options for omitting components of multimodality therapy.
Keywords: Cancer rectal localement évolué; Chemoradiation; Chimioradiothérapie; Chimiothérapie d’induction; Induction chemotherapy; Locally advanced rectal cancer; Thérapie néoadjuvante totale; Total neoadjuvant therapy.
Copyright © 2018 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources